Two Sigma Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Two Sigma Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-842,592	Closed	-$120M	–	1374
2025 Q4	$120M	Buy	842,592 +693,819	+466%	+$101M	0.23%	100
2025 Q3	$20.9M	Buy	+148,773	New	+$20.2M	0.04%	325
2025 Q2	–	Sell	-3,600	Closed	-$398K	–	2457
2025 Q1	$398K	Buy	+3,600	New	+$456K	﹤0.01%	1878
2024 Q4	–	Sell	-3,873	Closed	-$446K	–	2459
2024 Q3	$446K	Sell	3,873 -30,900	-89%	-$4.24M	﹤0.01%	1754
2024 Q2	$4.79M	Sell	34,773 -160,500	-82%	-$22M	0.01%	774
2024 Q1	$26.9M	Sell	195,273 -15,200	-7%	-$2.08M	0.06%	281
2023 Q4	$27.7M	Sell	210,473 -84,400	-29%	-$9.72M	0.06%	267
2023 Q3	$33.2M	Sell	294,873 -259,400	-47%	-$27.3M	0.09%	206
2023 Q2	$52.3M	Sell	554,273 -124,500	-18%	-$12.2M	0.13%	168
2023 Q1	$68.7M	Sell	678,773 -43,900	-6%	-$4.57M	0.18%	118
2022 Q4	$86.3M	Buy	722,673 +127,700	+21%	+$15M	0.24%	92
2022 Q3	$63.2M	Buy	594,973 +130,100	+28%	+$13.2M	0.18%	137
2022 Q2	$45.3M	Sell	464,873 -163,900	-26%	-$15.1M	0.13%	171
2022 Q1	$58.9M	Buy	628,773 +435,600	+225%	+$36.9M	0.16%	139
2021 Q4	$16.5M	Buy	193,173 +176,300	+1,045%	+$16.2M	0.04%	352
2021 Q3	$1.62M	Buy	+16,873	New	+$1.59M	﹤0.01%	1369
2020 Q4	–	Sell	-430,299	Closed	-$41.4M	–	2517
2020 Q3	$41.4M	Sell	430,299 -297,874	-41%	-$34.5M	0.12%	174
2020 Q2	$88.8M	Buy	728,173 +9,500	+1%	+$1.05M	0.26%	85
2020 Q1	$62.2M	Sell	718,673 -112,500	-14%	-$11M	0.24%	100
2019 Q4	$89.3M	Buy	831,173 +98,200	+13%	+$10.3M	0.21%	114
2019 Q3	$66M	Sell	732,973 -66,300	-8%	-$6.19M	0.16%	152
2019 Q2	$67.5M	Buy	799,273 +42,400	+6%	+$3.48M	0.17%	158
2019 Q1	$66.7M	Buy	756,873 +134,400	+22%	+$11.2M	0.17%	159
2018 Q4	$44.5M	Buy	622,473 +77,000	+14%	+$7.38M	0.12%	217
2018 Q3	$67.1M	Buy	545,473 +238,400	+78%	+$27M	0.16%	169
2018 Q2	$30.2M	Buy	307,073 +277,400	+935%	+$24.8M	0.08%	306
2018 Q1	$2.46M	Buy	29,673 +18,561	+167%	+$1.57M	0.01%	1152
2017 Q4	$862K	Buy	+11,112	New	+$758K	﹤0.01%	1573
2017 Q3	–	Sell	-11,600	Closed	-$534K	–	2303
2017 Q2	$534K	Sell	11,600 -6,900	-37%	-$335K	﹤0.01%	1772
2017 Q1	$801K	Hold	18,500	–	–	﹤0.01%	1687
2016 Q4	$716K	Buy	18,500 +11,327	+158%	+$513K	﹤0.01%	1699
2016 Q3	$363K	Buy	+7,173	New	+$357K	﹤0.01%	1815
2016 Q2	–	Sell	-39,973	Closed	-$1.58M	–	2145
2016 Q1	$1.58M	Buy	39,973 +10,400	+35%	+$413K	0.01%	905
2015 Q4	$1.67M	Sell	29,573 -37,500	-56%	-$1.91M	0.01%	808
2015 Q3	$2.68M	Buy	67,073 +48,500	+261%	+$2.34M	0.02%	653
2015 Q2	$887K	Buy	18,573 +2,600	+16%	+$110K	0.01%	1172
2015 Q1	$634K	Buy	+15,973	New	+$571K	﹤0.01%	1253
2014 Q4	–	Sell	-17,573	Closed	-$275K	–	2651
2014 Q3	$275K	Buy	+17,573	New	+$263K	﹤0.01%	1933
2014 Q1	–	Sell	-18,173	Closed	-$170K	–	2450
2013 Q4	$170K	Buy	+18,173	New	+$177K	﹤0.01%	2158
2013 Q3	–	Sell	-14,137	Closed	-$189K	–	2287
2013 Q2	$189K	Buy	+14,137	New	+$174K	﹤0.01%	1993

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's NBIX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 842,592 shares — an estimated $120M sold.

Two Sigma Advisers first reported a position in NBIX in Q2 2013 and held it in 40 quarters. The position peaked at $120M in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Two Sigma Advisers reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 842,592 Neurocrine Biosciences shares in Q1 2026, an estimated $120M.
Two Sigma Advisers first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 40 quarters.
Two Sigma Advisers's Neurocrine Biosciences position peaked at $120M in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.